Pulse Pharmaceuticals gets DCGI approval for nano Vitamin D3

Pulse Pharmaceuticals, a Hyderabad-based nano pharmaceutical drug delivery company, received approval from the India — Drugs Controller General of India (DCGI) for its nano-carrier entrapped Vitamin D3 oral dispersion. The approval, announced on August 20, 2026, follows clinical studies showing 50-60% higher serum vitamin D levels compared to conventional formulations. The product uses the company's proprietary Aqueol platform technology, designed to deliver lipophilic compounds in water-based mediums. Pulse Pharmaceuticals has been active in nano pharmaceutical drug delivery since 2010 and holds five granted patents across India, the United States, Russia, Mexico, and Australia, with an EU patent for Aqueol in final approval stages. The company is expanding its commercial presence across India, Southeast Asia, Africa, the Middle East, Russia-CIS, and Latin America, and planning collaborations in the US and Europe. Founder and Managing Director K. V. Rambabu stated that the approval is likely a first-of-its-kind globally and paves the way for regulatory approvals in highly regulated markets. The company already manufactures the product for pharmaceutical giants such as Abbott and Sanofi for the Indian market.